Matches in SemOpenAlex for { <https://semopenalex.org/work/W2114031829> ?p ?o ?g. }
- W2114031829 abstract "Management of type 2 diabetes with metformin often does not provide adequate glycemic control, thereby necessitating add-on treatment. In a 24-week clinical trial, dapagliflozin, an investigational sodium glucose cotransporter 2 inhibitor, improved glycemic control in patients inadequately controlled with metformin. The present study is an extension that was undertaken to evaluate dapagliflozin as long-term therapy in this population. This was a long-term extension (total 102 weeks) of a 24-week phase 3, multicenter, randomized, placebo-controlled, double-blind, parallel-group trial. Patients were randomly assigned (1:1:1:1) to blinded daily treatment (placebo, or dapagliflozin 2.5 to 5, or 10 mg) plus open-label metformin (≥1,500 mg). The previously published primary endpoint was change from baseline in glycated hemoglobin (HbA1c) at 24 weeks. This paper reports the follow-up to week 102, with analysis of covariance model performed at 24 weeks with last observation carried forward; a repeated measures analysis was utilized to evaluate changes from baseline in HbA1c, fasting plasma glucose (FPG), and weight. A total of 546 patients were randomized to 1 of the 4 treatments. The completion rate for the 78-week double-blind extension period was lower for the placebo group (63.5%) than for the dapagliflozin groups (68.3% to 79.8%). At week 102, mean changes from baseline HbA1c (8.06%) were +0.02% for placebo compared with -0.48% (P = 0.0008), -0.58% (P <0.0001), and -0.78% (P <0.0001) for dapagliflozin 2.5 to 5, and 10 mg, respectively. In addition, all dapagliflozin groups had sustained reductions from baseline in FPG (-1.07 to -1.47 mmol/l) and body weight (-1.10 to -1.74 kg) at 102 weeks, whereas increases were noted in placebo-treated patients for both of these outcomes. Events of hypoglycemia were rare and were not severe. Evidence suggestive of genital infection was reported in 11.7% to 14.6% of dapagliflozin patients and 5.1% of placebo patients, with one related discontinuation (dapagliflozin 5 mg). Evidence suggestive of urinary tract infection was reported in 8.0% to 13.3% of dapagliflozin patients and 8.0% of placebo patients, with one related discontinuation (dapagliflozin 2.5 mg). Dapagliflozin added to metformin for 102 weeks enabled sustained reductions in HbA1c, FPG, and weight without increased risk of hypoglycemia in patients with type 2 diabetes who were inadequately controlled on metformin alone. ClinicalTrials.gov: NCT00528879" @default.
- W2114031829 created "2016-06-24" @default.
- W2114031829 creator A5003809978 @default.
- W2114031829 creator A5012820598 @default.
- W2114031829 creator A5013313475 @default.
- W2114031829 creator A5034563714 @default.
- W2114031829 creator A5041155318 @default.
- W2114031829 creator A5059176189 @default.
- W2114031829 date "2013-02-20" @default.
- W2114031829 modified "2023-10-10" @default.
- W2114031829 title "Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial" @default.
- W2114031829 cites W1971851436 @default.
- W2114031829 cites W1973240292 @default.
- W2114031829 cites W2000047428 @default.
- W2114031829 cites W2008443217 @default.
- W2114031829 cites W2055594325 @default.
- W2114031829 cites W2081510795 @default.
- W2114031829 cites W2098458611 @default.
- W2114031829 cites W2109751567 @default.
- W2114031829 cites W2114276479 @default.
- W2114031829 cites W2122077393 @default.
- W2114031829 cites W2123984464 @default.
- W2114031829 cites W2127833912 @default.
- W2114031829 cites W2146901298 @default.
- W2114031829 cites W2149973065 @default.
- W2114031829 cites W2150855258 @default.
- W2114031829 cites W2155287847 @default.
- W2114031829 cites W4245367233 @default.
- W2114031829 doi "https://doi.org/10.1186/1741-7015-11-43" @default.
- W2114031829 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3820155" @default.
- W2114031829 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23425012" @default.
- W2114031829 hasPublicationYear "2013" @default.
- W2114031829 type Work @default.
- W2114031829 sameAs 2114031829 @default.
- W2114031829 citedByCount "255" @default.
- W2114031829 countsByYear W21140318292012 @default.
- W2114031829 countsByYear W21140318292013 @default.
- W2114031829 countsByYear W21140318292014 @default.
- W2114031829 countsByYear W21140318292015 @default.
- W2114031829 countsByYear W21140318292016 @default.
- W2114031829 countsByYear W21140318292017 @default.
- W2114031829 countsByYear W21140318292018 @default.
- W2114031829 countsByYear W21140318292019 @default.
- W2114031829 countsByYear W21140318292020 @default.
- W2114031829 countsByYear W21140318292021 @default.
- W2114031829 countsByYear W21140318292022 @default.
- W2114031829 countsByYear W21140318292023 @default.
- W2114031829 crossrefType "journal-article" @default.
- W2114031829 hasAuthorship W2114031829A5003809978 @default.
- W2114031829 hasAuthorship W2114031829A5012820598 @default.
- W2114031829 hasAuthorship W2114031829A5013313475 @default.
- W2114031829 hasAuthorship W2114031829A5034563714 @default.
- W2114031829 hasAuthorship W2114031829A5041155318 @default.
- W2114031829 hasAuthorship W2114031829A5059176189 @default.
- W2114031829 hasBestOaLocation W21140318291 @default.
- W2114031829 hasConcept C126322002 @default.
- W2114031829 hasConcept C134018914 @default.
- W2114031829 hasConcept C142724271 @default.
- W2114031829 hasConcept C168563851 @default.
- W2114031829 hasConcept C203092338 @default.
- W2114031829 hasConcept C204787440 @default.
- W2114031829 hasConcept C27081682 @default.
- W2114031829 hasConcept C2777180221 @default.
- W2114031829 hasConcept C2777422806 @default.
- W2114031829 hasConcept C2777538456 @default.
- W2114031829 hasConcept C2779306644 @default.
- W2114031829 hasConcept C2780323712 @default.
- W2114031829 hasConcept C2780473172 @default.
- W2114031829 hasConcept C2908647359 @default.
- W2114031829 hasConcept C555293320 @default.
- W2114031829 hasConcept C71924100 @default.
- W2114031829 hasConcept C99454951 @default.
- W2114031829 hasConceptScore W2114031829C126322002 @default.
- W2114031829 hasConceptScore W2114031829C134018914 @default.
- W2114031829 hasConceptScore W2114031829C142724271 @default.
- W2114031829 hasConceptScore W2114031829C168563851 @default.
- W2114031829 hasConceptScore W2114031829C203092338 @default.
- W2114031829 hasConceptScore W2114031829C204787440 @default.
- W2114031829 hasConceptScore W2114031829C27081682 @default.
- W2114031829 hasConceptScore W2114031829C2777180221 @default.
- W2114031829 hasConceptScore W2114031829C2777422806 @default.
- W2114031829 hasConceptScore W2114031829C2777538456 @default.
- W2114031829 hasConceptScore W2114031829C2779306644 @default.
- W2114031829 hasConceptScore W2114031829C2780323712 @default.
- W2114031829 hasConceptScore W2114031829C2780473172 @default.
- W2114031829 hasConceptScore W2114031829C2908647359 @default.
- W2114031829 hasConceptScore W2114031829C555293320 @default.
- W2114031829 hasConceptScore W2114031829C71924100 @default.
- W2114031829 hasConceptScore W2114031829C99454951 @default.
- W2114031829 hasIssue "1" @default.
- W2114031829 hasLocation W21140318291 @default.
- W2114031829 hasLocation W21140318292 @default.
- W2114031829 hasLocation W21140318293 @default.
- W2114031829 hasLocation W21140318294 @default.
- W2114031829 hasLocation W21140318295 @default.
- W2114031829 hasLocation W21140318296 @default.
- W2114031829 hasLocation W21140318297 @default.
- W2114031829 hasOpenAccess W2114031829 @default.
- W2114031829 hasPrimaryLocation W21140318291 @default.
- W2114031829 hasRelatedWork W1538553036 @default.